share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股SEC公告 ·  06/25 17:01

Moomoo AI 已提取核心訊息

Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.
Novo Integrated Sciences, Inc. has announced amendments to executive agreements with two key officers. On June 18, 2024, the company extended the term of the agreement with Robert Mattacchione, the CEO and Chairman of the Board, until June 18, 2025. This amendment follows the original executive agreement made on June 18, 2021, with GPE Global Holdings Inc., an entity controlled by Mattacchione. Similarly, an amendment was made to the executive agreement with Christopher David, extending his term as the Chief Operating Officer until June 18, 2025, and updating his title from President and Chief Operating Officer to solely Chief Operating Officer. These amendments are detailed in Exhibits 10.1 and 10.2, respectively, and are part of the company's Form 8-K filing with the SEC. The company's common stock is listed on the Nasdaq Capital Market under the trading symbol NVOS.
Novo Integrated Sciences,Inc.宣佈修改了兩名重要高管的執行協議。2024年6月18日,公司向董事長兼CEO Robert Mattacchione延長了協議有效期至2025年6月18日。該修訂版遵循了2021年6月18日與Mattacchione控制的GPE Global Holdings Inc.達成的原始執行協議。同樣,對於首席運營官Christopher David也進行了修訂,將其職位更新爲僅首席運營官,並將其任期延長至2025年6月18日。這些修訂內容分別列在展示文件10.1和10.2中,並作爲公司提交給SEC的8-K表格的一部分。公司的普通股在納斯達克上市,交易代碼爲NVOS。
Novo Integrated Sciences,Inc.宣佈修改了兩名重要高管的執行協議。2024年6月18日,公司向董事長兼CEO Robert Mattacchione延長了協議有效期至2025年6月18日。該修訂版遵循了2021年6月18日與Mattacchione控制的GPE Global Holdings Inc.達成的原始執行協議。同樣,對於首席運營官Christopher David也進行了修訂,將其職位更新爲僅首席運營官,並將其任期延長至2025年6月18日。這些修訂內容分別列在展示文件10.1和10.2中,並作爲公司提交給SEC的8-K表格的一部分。公司的普通股在納斯達克上市,交易代碼爲NVOS。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息